InsiderClue
Stocks · Health care · Biological Products, (No Diagnostic Substances)

Artiva Biotherapeutics, Inc.

ARTV Clue Score30
United States Fiscal year ends December CIK 0001817241
$6.94 +2.06% Close, 9 Oct 2026
Alert on the numbers Alert on insider trades
Price $6.94 +131.33% Close, 9 Oct 2026

Closing prices at the end of each trading day, from 19 Jul 2024. Not a live quote. Adjusted for share splits, so the line has no step at a split; dividends are not added back.

Revenue and profit

What the business sells, and what is left of it. Point at a year for the detail.
RevenueOperating incomeNet income
Fiscal year 2023Revenue32.9Operating income−30.7Net income−28.7EPS, diluted−35.78Fiscal year 2024Revenue0.3 −99.2%Operating income−67.3Net income−65.4EPS, diluted−5.81Fiscal year 2025Revenue0.0 −100.0%Operating income−89.8Net income−83.9EPS, diluted−3.43
FY2023FY2024FY2025
Revenue 32.9 0.3 0.0
Growth −99.2% −100.0%
Operating income −30.7 −67.3 −89.8
Net income −28.7 −65.4 −83.9
Growth
EPS, diluted −35.78 −5.81 −3.43

Margins

How much of each dollar of revenue it keeps. Point at a year for the detail.
Operating marginNet margin
Fiscal year 2023Operating margin−93.2%Net margin−87.2%Free cash flow margin−154.0%Fiscal year 2024Operating margin−26,805.6%Net margin−26,045.0%Free cash flow margin−22,180.9%Fiscal year 2025
FY2023FY2024FY2025
Operating margin −93.2% −26,805.6% n/a
Net margin −87.2% −26,045.0% n/a
Free cash flow margin −154.0% −22,180.9% n/a

Cash flow

The cash the business makes, what it reinvests, and what it hands back. Point at a year for the detail.
Operating cash flowCapital expenditureFree cash flow
Fiscal year 2023Operating cash flow−47.4Capital expenditure−3.3Free cash flow−50.7Fiscal year 2024Operating cash flow−55.0Capital expenditure−0.6Free cash flow−55.7Fiscal year 2025Operating cash flow−76.8Capital expenditure−2.6Free cash flow−79.3
FY2023FY2024FY2025
Operating cash flow −47.4 −55.0 −76.8
Capital expenditure −3.3 −0.6 −2.6
Free cash flow −50.7 −55.7 −79.3
Growth

Balance sheet

What it holds against what it owes, at each year end. Point at a year for the detail.
Cash
Fiscal year 2023Cash53.5Shareholders’ equity−162.0Fiscal year 2024Cash40.2Shareholders’ equity186.6Fiscal year 2025Cash26.7Shareholders’ equity110.0
FY2023FY2024FY2025
Cash 53.5 40.2 26.7
Shareholders’ equity −162.0 186.6 110.0

In millions of USD, except per-share figures and ratios. Fiscal years, as last filed with the SEC.

Financial statements FY2025 · 10-K

Ratios

Percentages worked out from the filed figures; debt to equity in times. Fiscal years ending December, each column as last filed with the SEC.
Click a line to chart it
Fiscal year FY2023 31 Dec 2023 FY2024 31 Dec 2024 FY2025 31 Dec 2025
Margins
−93.2% −26,805.6% n/a
−87.0% −26,045.0% n/a
−87.2% −26,045.0% n/a
−154.0% −22,180.9% n/a
Spending
152.6% 20,051.0% n/a
42.3% 6,854.6% n/a
9.9% 255.8% n/a
Returns
n/a −35.0% −76.3%
−27.3% −31.2% −64.0%
Balance and payout
48.2% 10.9% 16.0%